153
Participants
Start Date
September 20, 2018
Primary Completion Date
February 28, 2023
Study Completion Date
February 28, 2024
Belantamab mafodotin
Selected doses of belantamab mafodotin will be administered as an infusion.
Lenalidomide
Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
Dexamethasone
Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
Bortezomib
Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
GSK Investigational Site, Wollongong
GSK Investigational Site, Melbourne
GSK Investigational Site, Melbourne
GSK Investigational Site, Fitzroy
GSK Investigational Site, Woodville
GSK Investigational Site, Nedlands
GSK Investigational Site, Murdoch
GSK Investigational Site, Barcelona
GSK Investigational Site, New York
GSK Investigational Site, The Bronx
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Greer
GSK Investigational Site, Birmingham
GSK Investigational Site, Salamanca
GSK Investigational Site, Indianapolis
GSK Investigational Site, Lansing
GSK Investigational Site, St Louis
GSK Investigational Site, Grand Island
GSK Investigational Site, Dallas
GSK Investigational Site, Goodyear
GSK Investigational Site, Atlanta
GSK Investigational Site, Hackensack
GSK Investigational Site, Montreal
GSK Investigational Site, Truro
GSK Investigational Site, London
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
GlaxoSmithKline
INDUSTRY